"The DEA's marijuana approach is stuck in an outdated ‘war on drugs' mentality," said Duane Boise CEO of MMJ International Holdings. "While lawmakers push for medical progress, the DEA's red tape is suffocating innovation."
DEA officials, including Matt Strait and Thomas Prevoznik, have been accused of imposing unnecessary hurdles, such as slow-walking API Bulk Manufacturing registrations, and imposing opaque approval processes while patients continue to suffer.
Read MoreCompletion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets
Read More
Despite differences in characteristics and treatment, the pFCG test distinguished risk of the primary ischemic endpoint to a similar extent in the 2 groups.
No significant association was observed between pFCG and risk of bleeding.
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA
In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need
Read MorePartnership Raises FORME's Visibility with Affluent Customers, Highlights Brand's Seamless Integration into Premium Hospitality and Travel Environments
Installation adds to Hospitality Customers such as Four Seasons, Bulgari and Mandalay Bay Resort
Read MoreCandid Health Reports on Security, Availability, and Confidentiality Standards Established by The American Institute of Certified Public Accountants (AICPA) for its Candid Health Revenue Cycle Automation Platform.
Read MoreThe statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium
Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer subgroup
The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025, and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022
Read More
The global sexual wellness market is projected to surpass $125 billion by 2026, with the supplement industry experiencing rapid growth as consumers seek natural solutions for enhanced performance and vitality.
Read More
Duane Boise, CEO of MMJ International Holdings, expressed frustration over the contrasting approaches of federal agencies, stating, "While the FDA is facilitating medical innovation, the DEA's hindrance not only blocks scientific progress but also contradicts directives aimed at revitalizing domestic manufacturing." This situation starkly contrasts with the "Buy American" initiative endorsed by President Trump in 2020, which was intended to strengthen U.S. drug production capabilities and reduce dependence on foreign manufacturers.
Read MoreClick here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference
Click here to register for Jaguar's March 31 investor webcast
Company plans to file its annual report on March 31, 2025 on Form 10-K for the year ended December 31, 2024
Read More
As the federal government seeks to cut Medicaid expenses, the groundbreaking smart pill bottle technology can help by providing physicians, pharmacists and industry with improved medication adherence and prescription oversight and accountability.
Read More
Soft tissue injuries like UCL tears, hamstring pulls and oblique strains are more common early in the season, but non-invasive treatment technology, sam®Recover can help athletes recover faster and stay on the field.
Read MoreStrategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking.
Read More
"This is insanity," declares Duane Boise, CEO of MMJ International Holdings, echoing the sentiments of lawmakers and researchers alike. The 2020 House Oversight Committee hearing, and ongoing developments, have laid bare the Drug Enforcement Administration's (DEA) persistent obstruction of legitimate cannabis research, a battle MMJ has been fighting since their 2018 application. Despite bipartisan congressional outrage, as highlighted by Representative Earl "Buddy" Carter's scathing critique of the DEA's "epitome of ineptitude," and the agency's own hollow defenses, the DEA, represented by figures like Matthew Strait and Thomas Prevoznik, continues to delay and deny, hindering vital medical advancements. Boise's lawsuit against the DEA underscores the urgent need for reform, as the agency's actions not only impede scientific progress but also deny patients access to potentially life-changing treatments, a situation that demands immediate structural changes in federal cannabis policy.
Read More
Prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.
Duane Boise MMJ's CEO mentioned that “Thomas Prevoznik DEA Diversion DEPUTY ADMINISTRATOR 's adamant unwillingness to utilize his critical thinking faculties or examine his colossal stubbornness is captive to his unwarranted certainties which are holding him objectivity hostage”. The DEA's continued obstruction risks not only legal defeat but also reputational harm as patients await life-saving therapies.
Read MoreCompassion Center honors Danford "DanK" Koozer on his 80th birthday, recognizing his decades of fearless advocacy, grassroots leadership, and unwavering dedication to cannabis education through Willamette Valley NORML, Emerald Empire Hempfest, and over 750 episodes of Eugene Cannabis TV. His legacy continues to inspire a movement.
Read More
